Open AccessEmerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome
Author(s) -
András Perl
Publication year - 2009
Publication title -
current opinion in rheumatology/current opinion in rheumatology, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.452
H-Index - 112
eISSN - 1080-8175
pISSN - 1040-8711
DOI - 10.1097/bor.0b013e32832efe6b
Subject(s) - medicine , systemic lupus erythematosus , immunology , b cell activating factor , pathogenesis , histone deacetylase , b cell , autoantibody , cancer research , antibody , histone , biology , pathology , biochemistry , disease , gene
Systemic lupus erythematosus (SLE) and Sjogren's syndrome are chronic inflammatory diseases characterized by the dysfunction of T cells, B cells, and dendritic cells and the production of antinuclear autoantibodies. Here, we evaluate newly discovered molecular and cellular targets for the treatment of SLE and Sjogren's syndrome.